What causes resistance to post-attachment inhibitors in antiretroviral therapy of HIV infection?

Updated: Apr 18, 2019
  • Author: R Chris Rathbun, PharmD, BCPS (AQ-ID), AAHIVP; Chief Editor: John Bartlett, MD  more...
  • Print
Answer

Answer

Reduced ibalizumab susceptibility is associated with mutations that disrupt potential N-linked glycosolation sites (PNGS) in variable region 5 (V5) of HIV-1 envelope glycoproteins. Loss of glycan on the V5 N-terminus of gp120 is considered a major determinant of ibalizumab resistance. [102]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!